2. Academic Validation
  3. Glo1 inhibitors for neuropsychiatric and anti-epileptic drug development

Glo1 inhibitors for neuropsychiatric and anti-epileptic drug development

  • Biochem Soc Trans. 2014 Apr;42(2):461-7. doi: 10.1042/BST20140027.
Katherine M J McMurray 1,  Margaret G Distler 2,  Preetpal S Sidhu 3,  James M Cook 3,  Leggy A Arnold 3,  Abraham A Palmer,  Leigh D Plant 4
Affiliations

Affiliations

  • 1 *Committee on Neurobiology, University of Chicago, Chicago, IL 60637, USA.
  • 2 †Department of Pathology, University of Chicago, Chicago, IL 60637, U.S.A.
  • 3 ‡Department of Chemistry and Biochemistry, University of Wisconsin-Milwaukee, Milwaukee, WI 53211, U.S.A.
  • 4 ¶Department of Biochemistry, Brandeis University, Waltham, MA 02453, U.S.A.
PMID: 24646261 DOI: 10.1042/BST20140027
Abstract

Many current pharmacological treatments for neuropsychiatric disorders, such as anxiety and depression, are limited by a delayed onset of therapeutic effect, adverse side effects, abuse potential or lack of efficacy in many patients. These off-target effects highlight the need to identify novel mechanisms and targets for treatment. Recently, modulation of Glo1 (glyoxalase I) activity was shown to regulate anxiety-like behaviour and seizure-susceptibility in mice. These effects are likely to be mediated through the regulation of MG (methylglyoxal) by Glo1, as MG acts as a competitive partial agonist at GABA(A) (γ-aminobutyric acid A) receptors. Thus modulation of MG by Glo1 represents a novel target for treatment. In the present article, we evaluate the therapeutic potential of indirectly modulating MG concentrations through Glo1 inhibitors for the treatment of neuropsychiatric disorders.

Figures
Products